Salts 668

Abstract

A pharmaceutically acceptable salt of N-[2-(Diethylamino)ethyl]-N-(2-{[2-(4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-7-yl)ethyl]amino}ethyl)-3-[2-(1-naphthyl)ethoxy]propan amide provided it is not the dihydrobromide or dihydrochloride salt; and the use of such a compound as a medicament (for example in the treatment of respiratory diseases (such as asthma or COPD).

1 . A pharmaceutically acceptable salt of N-[2-(Diethylamino)ethyl]-N-(2-{[2-(4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-7-yl)ethyl]amino}ethyl)-3-[2-(1-naphthyl)ethoxy]propanamide provided it is not the dihydrobromide or dihydrochloride salt. 
   
   
       2 . A pharmaceutically acceptable salt as claimed in  claim 1 , wherein the salt is a trifluoroacetate, sulphate, phosphate, acetate, fumarate, maleate, citrate, pyruvate, succinate, oxalate, methanesulphonate, p-toluenesulphonate, bisulphate, benzenesulphonate, ethanesulphonate, malonate, xinafoate, ascorbate, oleate, nicotinate, saccharinate, adipate, formate, glycolate, L-lactate, D-lactate, aspartate, malate, L-tartrate, D-tartrate, stearate, 2-furoate, 3-furoate, napadisylate, edisylate, isethionate, 2-mesitylenesulphonate, 2-naphthalenesulphonate, D-mandelate, or L-mandelate. 
   
   
       3 . A pharmaceutically acceptable salt as claimed in  claim 1 , wherein the salt is a citrate salt. 
   
   
       4 . A processes for preparing a salt as claimed in  claim 1 , wherein the process comprises reacting an acid with N-[2-(Diethylamino)ethyl]-N-(2-{[2-(4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-7-yl)ethyl]amino}ethyl)-3-[2-(1-naphthyl)ethoxy]propanamide in a solvent. 
   
   
       5 . A pharmaceutical composition, wherein the composition comprises:
 a pharmaceutically acceptable salt as claimed in  claim 1 ; and   a pharmaceutically acceptable adjuvant, diluent, or carrier.   
   
   
       6 - 10 . (canceled) 
   
   
       11 . A method of treating, or reducing the risk of, a disease or condition in which modulation of β2 adrenoreceptor activity is beneficial, wherein the method comprises administering to a patient in need thereof a therapeutically effective amount of a pharmaceutically acceptable salt as claimed in  claim 1 . 
   
   
       12 . A method of treating, or reducing the risk of, an inflammatory disease or condition, wherein the method comprises administering to a patient in need thereof a therapeutically effective amount of a pharmaceutically acceptable salt as claimed in  claim 1 . 
   
   
       13 . A method of treating, or reducing the risk of, a disease or condition in a patient, wherein:
 the disease or condition is adult respiratory distress syndrome, pulmonary emphysema, bronchitis, bronchiectasis, chronic obstructive pulmonary disease, asthma, or rhinitis; and   the method comprises administering to the patient a therapeutically effective amount of a pharmaceutically acceptable salt as claimed in  claim 1 .   
   
   
       14 . A pharmaceutically acceptable salt as claimed in  claim 1 , wherein the salt is a ditosylate salt. 
   
   
       15 . A pharmaceutically acceptable salt as claimed in  claim 1 , wherein the salt is a phosphate salt. 
   
   
       16 . A pharmaceutically acceptable salt as claimed in  claim 1 , wherein the salt is a dixinafoate salt. 
   
   
       17 . A pharmaceutically acceptable salt as claimed in  claim 1 , wherein the salt is a sulfate salt. 
   
   
       18 . A pharmaceutically acceptable salt as claimed in  claim 1 , wherein the salt is a mono-benzoate salt. 
   
   
       19 . A pharmaceutically acceptable salt as claimed in  claim 1 , wherein the salt is a fumarate salt. 
   
   
       20 . A pharmaceutically acceptable salt as claimed in  claim 1 , wherein the salt is a besylate salt. 
   
   
       21 . A method as claimed in  claim 13 , wherein the salt is a citrate salt. 
   
   
       22 . A method as claimed in  claim 13 , wherein the salt is a ditosylate salt. 
   
   
       23 . A method as claimed in  claim 13 , wherein the salt is a phosphate salt. 
   
   
       24 . A method as claimed in  claim 13 , wherein the salt is a dixinafoate salt. 
   
   
       25 . A method as claimed in  claim 13 , wherein the salt is a sulfate salt. 
   
   
       26 . A method as claimed in  claim 13 , wherein the salt is a mono-benzoate salt. 
   
   
       27 . A method as claimed in  claim 13 , wherein the salt is a fumarate salt. 
   
   
       28 . A method as claimed in  claim 13 , wherein the salt is a besylate salt.